FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely to pulmonology, and can be used in the treatment of asthma. This method comprises administering to a patient with asthma a dose of 30 mg of benralizumab or its antigen-binding fragment once every four weeks for twelve weeks, and then once every eight weeks.
EFFECT: use of the invention allows to reduce the annual frequency of asthma attacks with good tolerance and safety of treatment.
9 cl, 4 tbl, 8 dwg, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS FOR INCREASING FORCED EXPIRATORY VOLUME IN ASTHMATIC PATIENTS USING BENRALIZUMAB | 2014 |
|
RU2703568C2 |
| METHODS FOR NORMALIZING ASTHMA SYMPTOMS USING BENRALIZUMAB | 2014 |
|
RU2728578C2 |
| METHODS OF TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH USE OF BENRALIZUMAB | 2014 |
|
RU2706729C2 |
| METHODS OF TREATING OR PREVENTING ASTHMA BY ADMINISTERING IL-4R ANTAGONIST | 2015 |
|
RU2713406C2 |
| METHODS FOR TREATMENT OR PREVENTION OF ASTHMA BY ADMINISTRATION OF IL-4R ANTAGONIST | 2018 |
|
RU2793745C2 |
| METHODS FOR DIAGNOSING AND TREATING RELATED TO TH2 INHIBITION | 2011 |
|
RU2578468C2 |
| DIAGNOSTICS AND TREATMENT METHODS ASSOCIATED WITH TH2 INHIBITION | 2011 |
|
RU2737245C2 |
| METHODS OF TREATING CHRONIC SINUSITIS WITH NASAL POLYPS BY ADMINISTERING IL-4R ANTAGONIST | 2015 |
|
RU2734490C2 |
| METHODS FOR TREATMENT OR PREVENTION OF ASTHMA BY ADMINISTERING IL-4R ANTAGONIST | 2013 |
|
RU2690675C2 |
| COMPOSITIONS AND METHODS FOR TREATING AND DIAGNOSING ASTHMA | 2009 |
|
RU2607569C2 |
